Adrucil, Fluorouracil
Adrucil, Fluorouracil Newswire

Adrucil, Fluorouracil Newswire

Comprehensive Real-Time News Feed for Adrucil, Fluorouracil (generic).

Results 1 - 20 of 215 in Adrucil, Fluorouracil (generic)

  1. Regeneron Pharmaceuticals, Inc. (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances ProfileRead the original story

    Friday | PR-inside.com

    Recently published research from GlobalData, "Regeneron Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile", is now available at Fast Market Research Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and manufactures pharmaceutical products for the treatment of serious ailments. The company's product portfolio helps treat various conditions related to inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, cancer and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders.

    Comment?

  2. Global Fluorouracil Industry 2015 Market Share, Research, Analysis, Trends, Growth and ForecastRead the original story w/Photo

    Thursday Jul 30 | SBWire

    The report is constructed on the basis of numerous components such as inputs and suggestions from industry leaders, located at various locations in order for being up to date on the present advances in the Fluorouracil market. The report also incorporates detailed instructions on the adopted business strategies that have proven to be quite substantial in the established markets, and additionally presents the key strategies could prove beneficial for the developing markets.

    Comment?

  3. Studies of human tumors by MRS: a review.Read the original story

    Wednesday Jul 29 | CiteULike

    The literature describing 31P, 1H, 13C, 23Na and 19F MRS in vivo in human cancers is reviewed. Cancers have typical metabolic characteristics in 31P and 1H MRS including high levels of phospholipid metabolites and a cellular pH more alkaline than normal.

    Comment?

  4. Teva expands recall of generic cancer drugRead the original story w/Photo

    Wednesday Jul 29 | Business Journal

    Teva Parenteral Medicines, a division of Teva Pharmaceutcal Industries Ltd., issued a voluntary recall for six lots of its generic cancer medicine Adrucil. The lots of the intravenous therapy were recalled, according to the company, because of the potential presence of particulate matter identified as an "aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals."

    Comment?

  5. Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of...Read the original story w/Photo

    Monday Jul 27 | US Recall News

    Teva Parenteral Medicines today announced a voluntary recall of six lots of AdrucilA A 5 g/100 mL due to the potential presence of particulate matter identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals. The recalled lots are as follows: The Food and Drug Administration is an agency within the U.S. Department of Health and Human Services.

    Comment?

  6. Select to View Firm Press ReleaseRead the original story

    Monday Jul 27 | US Food and Drug Administration

    FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

    Comment?

  7. Oral chemo raises hope for stomach cancer patientsRead the original story w/Photo

    Monday Jul 27 | The Times of India

    According to a new study, a combination of low dose tablets taken orally promises to be not just a cost effective chemotherapy but is also showing positive results in terms of survival rate. CHENNAI: The fact that there is no standard treatment for patients with gastric cancer has proved disastrous for many.

    Comment?

  8. Press release: Super graphene helps boost chemotherapy treatmentRead the original story

    Thursday Jul 9 | Nanotechweb.org

    Chemotherapy treatment usually involves the patient receiving medicine through an intravenous catheter. These catheters, as well as the the equipment attached to them, are treated with a silver coating which is antibacterial, preventing bacterial growth and unwanted infections during a treatment.

    Comment?

  9. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Friday Jul 24 | Business Wire

    Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil 5 g/100 mL Due to Particulate Matter )--Teva Parenteral Medicines today announced a voluntary recall of six lots of AdrucilA 5 g/100 mL due to the potential pres... )--FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code --SCAN Health Plan VP of Pharmacy, Sharon Jhawar, PharmD, MBA, CGP, to be Featured in National Webinar on Improving Care for Older Adults on August 6 from 1-2:30 ... )--Geospace Technologies today announced that it will release third quarter 2015 financial results on Thursday, August 6, 2015 after the market closes.

    Comment?

  10. Lilly Reports Second-Quarter 2015 Results, Revises 2015 Financial GuidanceRead the original story

    Thursday Jul 23 | Freshnews

    Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with generally accepted accounting principles and include all revenue and expenses recognized during the period.

    Comment?

  11. Now Available: Fennec Pharmaceuticals Inc. (FRX) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Tuesday Jul 21 | PR-inside.com

    Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.

    Comment?

  12. Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitroRead the original story

    Thursday Jul 16 | CiteULike

    Purpose: Proliferative vitreoretinopathy is characterizedby the formation of cellular membranes on the detached retina and also in the vitreous. Glial cellscan be found in epiretinal and subretinal membranes from eyes with PVR, proliferative diabeticretinopathy , idiopathic macular pucker, uveitis and other diseases affecting theretina.

    Comment?

  13. Phase 3 RECOURSE Trial Holds Promise for Colorectal CancerRead the original story

    Monday Jul 13 | The American Journal of Managed Care

    A poster presented at the 2015 annual meeting of the American Society of Clinical Oncology shared encouraging phase 3 survival data from the RECOURSE trial, after evaluating specific geographic subgroups. Colorectal cancer, with a 5-year survival of 64.9%, is projected to result in 8.4% of all cancer deaths in 2015.1 The 5-year survival for patients with localized disease is even better, at 90.1%.

    Comment?

  14. Chemotherapy equipment dangerous: StudyRead the original story

    Saturday Jul 11 | Nerve News

    The anti-bacterial silver coating used in chemotherapy catheters actually breaks down the drugs and thus reduces the efficacy of the treatment, a study says. Chemotherapy treatment usually involves the patient receiving medicine through an intravenous catheter.

    Comment?

  15. Super graphene can help treat cancerRead the original story w/Photo

    Saturday Jul 11 | DNA India

    Chemotherapy treatment usually involves the patient receiving medicine through an intravenous catheter. These catheters, as well as the equipment attached to them, are treated with a silver coating which is antibacterial, preventing bacterial growth and unwanted infections during a treatment.

    Comment?

  16. Study Uncovers Simple Way to Boost Chemo EffectivenessRead the original story w/Photo

    Friday Jul 10 | News Max

    Antibacterial coatings on catheters used to deliver chemotherapy can hinder its effectiveness, new research suggests. The good news, reported by researchers with the Norwegian University of Science and Technology in Trondheim, is that switching to other types of catheter materials such as graphene may be a simple way to greatly boost the effectiveness of chemo, according to Medical News Today .

    Comment?

  17. Graphene coating on catheters may improve chemo effectivenessRead the original story

    Friday Jul 10 | Medical News Today

    Chemotherapy is a type of cancer treatment that uses powerful chemicals to destroy cancer cells. It is usually delivered directly into the patient's veins using a catheter.

    Comment?

  18. Antimicrobial silver coatings could be hindering your chemoRead the original story w/Photo

    Thursday Jul 9 | Engadget

    Hospitals around the world use a silver coating on their chemotherapy equipment, such as IV catheters, because the noble metal prevents microbial growth. However, it turns out that this germ killing coating could be damaging chemo drugs that flow over it and harming patients.

    Comment?

  19. FDA Grants Fast Track Designation To Tocagen Inc.'s Toca 511 & Toca...Read the original story

    Wednesday Jul 8 | BioSpace

    FDA Grants Fast Track Designation To Tocagen Inc. 's Toca 511 & Toca FC For Treatment Of Recurrent High Grade Glioma /PRNewswire/ -- Tocagen Inc. , a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to its lead immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma. This treatment will enter a registrational study called Toca 5 later this year in patients with recurrent glioblastoma or anaplastic astrocytoma.

    Comment?

  20. FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca...Read the original story

    Thursday Jul 9 | Freshnews

    Tocagen Inc. , a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to its lead immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma. This treatment will enter a registrational study called Toca 5 later this year in patients with recurrent glioblastoma or anaplastic astrocytoma.

    Comment?